CorMedix anticipates net price erosion starting in Q2 2025, factoring it into revenue guidance. They are supporting contracted LDOs for upcoming orders and engaging smaller providers. The TPN program targets vulnerable patients, and a CMMI policy change led to increased patient numbers.
Read MoreDid you find this insightful?
Amazing
Bad
Just Okay